Interestingly, NCL is viewed as a target for cancer therapy, and our studies further show that some pre-B ALL cells are sensitive to anti-NCL treatment using AS1411, a DNA aptamer that specifically binds NCL. This evidence concerns the gene NUCLEOLIN and cancer.